Skip to main content
SpringerLink
Log in

Safety analysis of high dose (>6 mg/kg/day) daptomycin in patients with concomitant statin therapy

  • Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

There is a paucity of data regarding efficacy and safety of concomitant therapy of daptomycin and statins, so we reviewed patients that concomitantly received daptomycin and statins to identify any potential increase in toxicity in our cohort. This retrospective study included all patients that received >6 mg/kg/day of daptomycin along with statins and had efficacy and safety data. Patients on high dose (>6 mg/kg/day) daptomycin therapy that did not received statins served as controls. One hundred four patients were included. Median daptomycin dose was 7.8 mg/kg/day (range 6.5–10.8 mg/kg/day), for a mean duration of therapy of 17 days (range 10–51 days). Thirty-six patients received daptomycin and statins and 68 received only daptomycin. Muscular toxicity defined as CPK levels > 1000 UI/L (2.5 times upper normal limit, range of determination 200–400 UI/L) was equally distributed between both groups (3/36, 8% vs 7/68, 10%; p = 0.746). Despite biochemical toxicity, we did not find clinical toxicity and daptomycin treatment was completed in all cases. We did not find predictors of increased CPK during daptomycin therapy. Based on our data, concomitant administration of daptomycin and statins is safe and is not associated with an increased risk of rhabdomyolysis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Baltz RH (2009) Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. Curr Opin Chem Biol 13(2):144–151

    Article  PubMed  CAS  Google Scholar 

  2. Hobbs JK, Miller K, O'Neill AJ, Chopra I (2008) Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus. J Antimicrob Chemother 62(5):1003–1008

    Article  PubMed  CAS  Google Scholar 

  3. Figueroa DA, Mangini E, Amodio-Groton M, Vardianos B, Melchert A, Fana C, Wehbeh W, Urban CM, Segal-Maurer S (2009) Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 49(2):177–180

    Article  PubMed  CAS  Google Scholar 

  4. Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC (2009) Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy. Ann Pharmacother 43(7):1211–1219

    Article  PubMed  CAS  Google Scholar 

  5. Parra-Ruiz J, Pena-Monje A, Tomas-Jimenez C, Pomares-Mora J, Hernandez-Quero J (2011) Efficacy and safety of high dose (>/=8 mg/kg/day) daptomycin. Enferm Infecc Microbiol Clin 29(6):425–427

    Article  PubMed  Google Scholar 

  6. Wu G, Abraham T, Rapp J, Vastey F, Saad N, Balmir E (2011) Daptomycin: evaluation of a high-dose treatment strategy. Int J Antimicrob Agents 38(3):192–196

    Article  PubMed  CAS  Google Scholar 

  7. Katz DE, Lindfield KC, Steenbergen JN, Benziger DP, Blackerby KJ, Knapp AG, Martone WJ (2008) A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int J Clin Pract 62(9):1455–1464

    Article  PubMed  CAS  Google Scholar 

  8. Sauermann R, Rothenburger M, Graninger W, Joukhadar C (2008) Daptomycin: a review 4 years after first approval. Pharmacology 81(2):79–91

    Article  PubMed  CAS  Google Scholar 

  9. Pai MP, Norenberg JP, Anderson T, Goade DW, Rodvold KA, Telepak RA, Mercier RC (2007) Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother 51(8):2741–2747

    Article  PubMed  CAS  Google Scholar 

  10. Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49(2):71–87

    Article  PubMed  CAS  Google Scholar 

  11. Fenton C, Keating GM, Curran MP (2004) Daptomycin. Drugs 64(4):445–455, discussion 457–448

    Article  PubMed  CAS  Google Scholar 

  12. Odero RO, Cleveland KO, Gelfand MS (2009) Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor. J Antimicrob Chemother 63(6):1299–1300

    Article  PubMed  CAS  Google Scholar 

  13. Chang JT, Staffa JA, Parks M, Green L (2004) Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 13(7):417–426

    Article  PubMed  CAS  Google Scholar 

  14. Farnier M (2011) Safety review of combination drugs for hyperlipidemia. Expert Opin Drug Saf 10(3):363–371

    Article  PubMed  CAS  Google Scholar 

  15. Kostrominova TY, Hassett CA, Rader EP, Davis C, Larkin LM, Coleman S, Oleson FB, Faulkner JA (2010) Characterization of skeletal muscle effects associated with daptomycin in rats. Muscle Nerve 42(3):385–393

    Article  PubMed  Google Scholar 

  16. Kostrominova TY, Coleman S, Oleson FB, Faulkner JA, Larkin LM (2010) Effect of daptomycin on primary rat muscle cell cultures in vitro. Vitro Cell Dev Biol Anim 46(7):613–618

    Article  CAS  Google Scholar 

  17. Sirvent P, Mercier J, Lacampagne A (2008) New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol 8(3):333–338

    Article  PubMed  CAS  Google Scholar 

  18. Berg ML, Estes L, Enzler MJ (2011) Effect of daptomycin with and without concurrent statin therapy on creatine phosphokinase (CPK) values. Abstract #A-1685, 51st ICAAC, Chicago, September 17–20

  19. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL (2010) Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 50(12):1568–1574

    Article  PubMed  CAS  Google Scholar 

  20. Crompton JA, North DS, McConnell SA, Lamp KC (2009) Safety and efficacy of daptomycin in the treatment of osteomyelitis: results from the CORE Registry. J Chemother 21(4):414–420

    PubMed  CAS  Google Scholar 

  21. Chamberlain RS, Culshaw DL, Donovan BJ, Lamp KC (2009) Daptomycin for the treatment of surgical site infections. Surgery 146(2):316–324

    Article  PubMed  Google Scholar 

  22. Sakoulas G (2009) Clinical outcomes with daptomycin: a post-marketing, real-world evaluation. Clin Microbiol Infect 15(Suppl 6):11–16

    Article  PubMed  CAS  Google Scholar 

  23. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA, Chambers HF (2011) Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52(3):e18–e55

    Article  PubMed  Google Scholar 

Download references

Funding

No funding was provided for the realization of this work.

Transparency declaration

JPR has received honoraria, consultancy fees and funding research from Novartis, Pfizer and Astellas. JHQ has received honorary and consultancy fees from Novartis and Pfizer.

Author information

Authors and Affiliations

  1. Servicio de Enfermedades Infecciosas, Hospital Universitario San Cecilio, Avda. Dr Olóriz 16, 18012, Granada, Spain

    J. Parra-Ruiz, C. Tomás-Jiménez & J. Hernández-Quero

  2. Servicio de Medicina Interna, Complejo Asistencial Unversitario, Burgos, Spain

    C. Dueñas-Gutiérrez

  3. Servicio de Medicina Interna, Hospital Universitario Reina Sofía, Murcia, Spain

    C. Tomás-Jiménez

  4. Servicio de Angiología y Cirugía Vascular, Hospital Universitario San Cecilio, Granada, Spain

    J. P. Linares-Palomino

  5. Servicio Cirugía Ortopédica y Traumatología, Hospital Universitario San Cecilio, Granada, Spain

    J. Garrido-Gomez

Authors
  1. J. Parra-Ruiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Dueñas-Gutiérrez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Tomás-Jiménez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. P. Linares-Palomino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Garrido-Gomez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Hernández-Quero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Parra-Ruiz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Parra-Ruiz, J., Dueñas-Gutiérrez, C., Tomás-Jiménez, C. et al. Safety analysis of high dose (>6 mg/kg/day) daptomycin in patients with concomitant statin therapy. Eur J Clin Microbiol Infect Dis 31, 1771–1774 (2012). https://doi.org/10.1007/s10096-011-1500-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-011-1500-y

Keywords

Search

Navigation